Brief: ANI Pharmaceuticals Q1 Adjusted EPS USD 1.21 Vs. IBES Estimate USD 1
10/05/2024 11:50
May 10 (Reuters) - ANI Pharmaceuticals Q1 revenue USD 137.43 million vs. IBES estimate USD 126 million. * Q1 net income USD 17.8 million * Q1 operating expenses USD 117.1 million * outlook FY adjusted EBITDA USD 135-145 million * outlook FY adjusted EPS USD 4.26-4.67
Recent news on ANI Pharmaceuticals
See all newsBrief: Ani Pharmaceuticals Announces The Launch Of Duloxetine Delayed-Release Capsules
Brief: Ani Pharmaceuticals Announces The FDA Approval Of Everolimus Tablets For Oral Suspension
Brief: Ani Pharmaceuticals Appoints Henry Gosebruch To Board Of Directors
U.S. RESEARCH ROUNDUP-Compass Minerals, Duke Energy, Tesla
ANI Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary